GPC2 as an Immunotherapeutic Target in Medulloblastoma and other Pediatric Brain Tumors

Email Principal Investigator
Ongoing
Specimen
Medulloblastoma
HGG
(AT/RT)
Asset 15.png
BOSSE_KRISTOPHER.original.jpg

Kristopher Bosse

CBTN Specimen

8

CBTN Participants

4

CBTN Samples

CBTN Pre-clinical Models Used

Backer

Alex's Lemonade Stand Foundation

Damon Runyon

HHOW

About this

Project

Medulloblastoma and other pediatric brain cancers could be candidates for immunotherapy, a therapy that utilizes a patient’s own immune system to attack a tumor. Immunotherapy requires molecular targets and medulloblastomas and other brain tumors differentially express cell surface molecules that could act as targets. The recently FDA-approved chimeric antigen receptor (CAR) T cell therapy (a type of immunotherapy) for acute lymphoblastic leukemia, pioneered at the Children's Hospital of Philadelphia, provides proof that immunotherapies can combat pediatric cancers. Challenges remain in identifying molecules that meet optimal immunotherapeutic safety and efficacy criteria for use in the pediatric patient population. Researchers have recently discovered that the signaling co-receptor glypican-2 (GPC2) meets these criteria in both medulloblastomas and neuroblastomas. GPC2 is a highly expressed medulloblastoma and neuroblastoma cell surface molecule that is not detectable at significant levels on normal pediatric tissues. The group has developed a GPC2-directed antibody-drug conjugate (ADC) that potently inhibits the growth of neuroblastoma in animal models. However, the efficacy of this ADC in medulloblastoma models remains undefined. Researchers have also found that GPC2 may be overexpressed in other lethal pediatric brain tumors, such as high-grade gliomas (HGGs), peripheral neuroectodermal tumors (PNETs) (including the universally lethal embryonal tumors with multilayered rosettes [ETMRs]), and atypical teratoid rhabdoid tumors (ATRTs). The central hypothesis of this project is that targeting GPC2 with the identified ADC in medulloblastoma and other GPC2-expressing pediatric brain tumors will lead to better outcomes for patients. The Children's Brain Tumor Network contributed cell lines and tissue in freezing media necessary to develop the models needed for this line of research.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

The main goal of this project is to determine whether targeting GPC2 is a viable option for the immunotherapeutic treatment of various pediatric brain cancers.

What is the impact of this project?

Researchers hypothesize that if proven a successful therapeutic target, GPC2 related therapies could lead to much better outcomes for pediatric brain cancer patients.

Why is the CBTN request important to this project?

The Children’s Brain Tumor Network provided cell lines and high quality frozen specimens integral to this research.

Specimen Data

The Children's Brain Tumor Network contributed cell lines and tissue in freezing media for in vitro studies.